Sunrise New Energy Announces Invention of Porous Carbon-Coated Graphite Composite Material for Energy Storage Batteries, Targeting High-Performance Storage for Data Centers

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) announced that final results from its Phase 1 alpha-lactalbumin (aLA) breast cancer vaccine trial will be presented at the 2025 San Antonio Breast Cancer Symposium on December 11, 2025 (5:00–6:30 PM CST, Poster PS4-06-19, Abstract 765).

The trial was conducted at Cleveland Clinic and funded by a U.S. Department of Defense grant. Comprehensive blood and tissue analyses are underway and a full report will be submitted to the Department of Defense and the U.S. Food and Drug Administration to inform Phase 2 planning.

Positive

• Final Phase 1 results scheduled for presentation on Dec 11, 2025
• Trial conducted at Cleveland Clinic with institutional involvement
• Funded by a U.S. Department of Defense grant
• Data will be submitted to FDA to inform Phase 2 planning

Negative

• Press release does not disclose quantitative efficacy or safety metrics

Market Context

This announcement adds to Sunrise New Energy’s string of developments in advanced battery and energy...

Analysis

This announcement adds to Sunrise New Energy’s string of developments in advanced battery and energy‑storage materials, complementing prior patents, pilot funding of USD 345,000, and a 10,000‑ton anode supply contract valued near $30 million. At the same time, recent public and private offerings at $0.55–$0.80, historical net losses of $23,124,402, and going‑concern language in filings underline financial and dilution risk. Investors may watch for revenue realization, cash usage, and further capital‑raising activity.

Key Figures

Private placement gross proceeds: $5,600,000 Public offering gross proceeds: $1,650,000 Public offering net proceeds: $1,624,000 +5 more

8 metrics

Private placement gross proceeds $5,600,000 7,000,000 shares and 3,500,000 warrants at $0.80 (Regulation S, 6-K 2025-11-19)

Public offering gross proceeds $1,650,000 Class A shares at $0.55 (424B5 dated 2025-10-03)

Public offering net proceeds $1,624,000 After ~$26,000 expenses (424B5 dated 2025-10-03)

Earlier public offering gross $550,000 Class A shares at $0.55 (424B5 dated 2025-09-23)

Net loss (example period) $23,124,402 Consolidated net loss referenced in 424B5 dated 2025-10-03

Intercompany loans $6,188,307 Historical intercompany loans disclosed in 424B5 dated 2025-10-03

Joint venture capital US$1.0 million Initial capital for Alchemistica Inc. JV (6-K dated 2025-08-08)

Abstract Number 765 Breast cancer vaccine Phase 1 final results abstract at SABCS 2025

Historical Context

5 past events · Latest: Dec 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 05	Battery patent grant	Positive	-7.0%	China patent on fast-charging silicon-carbon composite anode materials.
Dec 04	Solid-state patent	Positive	+6.0%	Patent for lithium cerate–coated graphite iron oxide anode method.
Dec 04	Pilot project funding	Positive	+6.0%	USD 345,000 award for solid-state battery and key materials pilot.
Dec 02	Supply contract	Positive	-0.9%	One-year USD 30M contract for 10,000 tons of graphite anode.
Oct 22	AI control patent	Positive	+1.9%	Patent for AI-driven multivariable particle size control system.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent technology and contract news has often been positive while price reactions were mixed, with both aligned gains and occasional selloffs on good news.

Recent Company History

Over the last few months, Sunrise New Energy reported several technology and commercial milestones. On Dec 2, it signed a 10,000-ton, roughly $30 million annual supply contract for synthetic graphite anode materials. On Dec 4–5, the company secured a USD 345,000 pilot project grant and multiple patents for solid-state and fast-charging anode technologies. Earlier, on Oct 22, it highlighted an AI-driven particle size control patent. Price reactions alternated between gains and pullbacks, indicating investors have not consistently rewarded positive developments.

Key Terms

phase 1, phase 2, immunogenicity, alpha-lactalbumin, +4 more

8 terms

phase 1 medical

"final results from the Phase 1 clinical trial of its breast cancer vaccine"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

phase 2 medical

"to inform FDA discussions and advance Phase 2 development plans"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

immunogenicity medical

"evaluated the safety and immunogenicity of an alpha-lactalbumin (aLA) vaccine"

Immunogenicity is the ability of a substance, such as a vaccine or medication, to provoke an immune response in the body. It matters to investors because high immunogenicity can affect the effectiveness and safety of a product, potentially leading to increased costs or regulatory challenges. Understanding immunogenicity helps assess the long-term viability and market potential of pharmaceutical and biotech investments.

alpha-lactalbumin medical

"immunogenicity of an alpha-lactalbumin (aLA) vaccine for breast cancer"

Alpha-lactalbumin is a protein naturally found in mammalian milk that helps produce lactose (milk sugar) and supplies key amino acids, notably tryptophan. Investors care because it is used as an ingredient in infant formulas, medical nutrition and dietary supplements, and can affect product claims, manufacturing costs and regulatory review—think of it as a specialty ingredient that can change a food or drug product’s nutritional value and market appeal.

poster presentation technical

"Poster Presentation: Thursday, December 11, 2025, 5:00–6:30 PM CST"

A poster presentation is a visual display of information, often used to share research findings or ideas at conferences or meetings. It usually consists of a large printed poster that summarizes key points, allowing viewers to quickly understand the main message and ask questions. For investors, it highlights important developments or insights in a clear, accessible way, helping them stay informed about new opportunities or trends.

form 6-k regulatory

"has filed a Form 6-K to furnish materials related to its upcoming"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

form d regulatory

"filed a Form D notice reporting a Regulation D, Rule 506(b) equity offering"

Form D is a short notice filed with the U.S. Securities and Exchange Commission when a company raises money using a private offering exemption instead of a full public registration. Think of it as a public receipt that lists basic facts about the fundraiser—amount sought, how much has been sold, and who the issuer is—without the full audited disclosures of a public offering. Investors use it to spot private financings, assess potential dilution or fundraising activity, and find contact information, but it is not a substitute for detailed due diligence.

regulation s regulatory

"issued the shares and warrants under Regulation S, which applies to offerings"

Regulation S is a set of rules that allows companies to sell securities (like shares or bonds) to investors outside the United States without having to follow all U.S. securities laws. It matters because it makes it easier for companies to raise money from international investors while still complying with U.S. regulations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DOVER, USA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Sunrise New Energy Co., Ltd. (“Sunrise”, the “Company”, “we” or “our”) (NASDAQ: EPOW) today announced the invention patent "A Porous Carbon-Coated Graphite Composite Material for Energy Storage Batteries and Its Preparation Method" (Patent Application No.: 2025106594980) . This technology focuses on the structural and process design for next-generation anode materials in energy storage batteries. It is expected to further solidify Sunrise's technical advantages in the energy storage sector and enhance the Company's core competitiveness in the global energy storage market.

With the rapid development of applications such as large-scale energy storage power stations, energy storage for commercial and industrial parks, and data center Battery Energy Storage Systems (BESS), market demand for high-performance anode materials for energy storage batteries is booming. Currently, leading global cloud computing and data center operators are extensively adopting lithium-ion batteries as the core technical solution for UPS and BESS, while actively monitoring next-generation battery technologies with higher safety and energy density. Sunrise's innovation in porous carbon-coated graphite composite materials for energy storage batteries will provide the material foundation and technical support for the Company's entry into high-end application scenarios such as data center energy management, commercial and industrial energy storage, and grid-side peak shaving, indicating broad prospects for the industrialization of related technologies.

“We will continue to invest in research and development of key anode materials for energy storage and solid-state batteries.  ” said Haiping Hu, Founder and CEO of Sunrise. “The Company is committed to building a comprehensive energy storage material technology platform for various scenarios including grid-side, commercial and industrial-side, and data center applications, thereby consolidating and expanding its competitive advantage in the global energy storage battery anode material field.”

About Sunrise New Energy Co., Ltd

Headquartered in Zibo, Shandong Province, China, Sunrise New Energy Co., Ltd., through its joint venture, is engaged in the manufacturing and sale of graphite anode material for lithium-ion batteries. The Company's joint venture has completed the construction of a manufacturing facility with a production capacity of 50,000 tons in Guizhou Province, China. The plant runs on inexpensive electricity from renewable sources, which helps to make Sunrise New Energy a low-cost and low–environmental-impact producer of graphite anode material. Mr. Haiping Hu, the founder and CEO of the Company, is a major pioneer for the graphite anode industry in China starting from 1999. The Company’s management team is also composed of experts with years of experiences and strong track-records of success in the graphite anode industry. In addition, the Company also operates a knowledge sharing platform in China. For further information, please visit the Company’s website at www.sunrisenewenergy.com.

Forward-looking statement

Certain statements in this press release regarding the Company's future expectations, plans and prospects constitute forward-looking statements as defined by Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements about plans, goals, objectives, strategies, future events, expected results, assumptions and any other factual statements that have not occurred. Any words that refer to "may", "will", "want", "should", "believe", "expect", "expect", "estimate", "estimate" or similar non-factual words, shall be regarded as forward-looking statements. Due to various factors, the actual results may differ materially from the historical results or the contents expressed in these forward-looking statements. These factors include, but are not limited to, the company's strategic objectives, the company's future plans, market demand and user acceptance of the company's products or services, technological updates, economic trends, the company's reputation and brand, the impact of industry competition and bidding, relevant policies and regulations, the ups and downs of China's macroeconomic conditions, the relevant international market conditions, and other related risks and assumptions disclosed in the Company’s Annual Report on Form 20-F published on the SEC’s website. In view of the above and other related reasons, we urge investors to visit the SEC’s website and consider other factors that may affect the Company's future operating results. The Company is under no obligation to make public amendments to changes in these forward-looking statements unless required by law.

For more information, please contact:

The Company:
IR Department
Email: IR@sunrisenewenergy.com
Phone: +86 4009919228

FAQ

When will Anixa (NASDAQ: ANIX) present Phase 1 aLA vaccine results at SABCS?

Anixa will present on December 11, 2025, 5:00–6:30 PM CST (Poster PS4-06-19, Abstract 765).

What trial site and funding supported Anixa's Phase 1 aLA breast cancer vaccine study?

The trial was conducted at Cleveland Clinic and funded by a U.S. Department of Defense grant.

Will Anixa submit its Phase 1 data to regulators for Phase 2 planning (ANIX)?

Yes. A full report will be submitted to the U.S. Department of Defense and the FDA to inform Phase 2 discussions.

Does the December 11, 2025 SABCS presentation include detailed blood and tissue analyses for ANIX?

The company says comprehensive blood and tissue analyses are underway and will be part of the detailed data release.

Are numeric efficacy or safety results included in the Anixa press release for ANIX?

No. The press release does not provide quantitative efficacy or safety metrics.

Who will deliver the Anixa Phase 1 aLA vaccine presentation at SABCS?

The presentation will be delivered by Justin Johnson, Ph.D., Program Manager at Cleveland Clinic and co-inventor of the vaccine technology.